Description: The instructions for acarbose tablets were issued by the State Administration of Pharmaceutical Products on February 5, 2002 in the Notice on Publishing the Catalogue of Instructions for the Second Batch of Chemicals. The instructions published by the State Administration of Pharmaceutical Products are reference samples for revising the specifications. In case of doubt, the enterprise may propose amendments. Indications should be consistent with the original approval; Adverse reactions, drug interactions and other contents, the instructions provided by the enterprise can not be less than those listed in the sample draft. For empty or incomplete items in the sample manual, enterprises should be required to fill in according to the actual situation, such as product name and specifications.
Drug name
Generic name: acarbose tablets
Former name:
Commodity name:
English name: Acarbose tablets
Chinese Pinyin: Tɑnɡ
The main component of this product is acarbose, and the main component is O4,6 dideoxy 4 [(1s, 4r, 5s, 6s) 4,5,6 trihydroxy 3 (hydroxymethyl) 2 cyclohexene] amino ](D glucopyranosyl (1→4)O(D glucopyranosyl (/kl)
Structural formula:
Molecular formula:
Molecular weight:
Character; Role; letter
This product is a white or light yellow tablet.
pharmacological action
This product is an oral hypoglycemic agent. The mechanism of its hypoglycemic effect is to inhibit the competition between intestinal parietal cells and oligosaccharides, reversibly bind with a glucosidase, and inhibit the activity of the enzyme, thus delaying the degradation of carbohydrates, causing slow absorption of intestinal glucose and reducing the increase of postprandial blood sugar.
pharmacokinetics
This drug is rarely absorbed after oral administration, which avoids the adverse reactions caused by absorption. Its prototype bioavailability is only 1% ~ 2%. After oral administration of 200mg, t 1/2 was 3.7 hours, and the elimination of t 1/2 was 9.6 hours. The binding rate of plasma protein is low, which is mainly degraded in the intestine or excreted with feces for 8 hours in its original form.
indicate
Diet control for type 2 diabetes.
dosage
Swallow the whole tablet immediately before meals, or chew it with the first few bites of food. Dosage varies from person to person. The general recommended dose is: the initial dose is 50mg each time, three times a day. Then gradually increase to 0. 1g each time, three times a day. In some cases, it can be increased to 0.2g each time, three times a day. Still follow the doctor's advice.
counteraction
There are often flatulence and bowel sounds, occasional diarrhea and little abdominal pain. If you don't control your diet, it may aggravate the gastrointestinal side effects. If you still have severe discomfort after controlling your diet, you should consult your doctor and reduce the dose temporarily or permanently. Individual cases may have skin allergic reactions such as erythema, rash and urticaria.
taboo
(1) Acarbose allergy is prohibited.
(2) diabetic coma and coma, acidosis or ketosis patients are prohibited.
(3) Patients with chronic gastrointestinal dysfunction with obvious digestive and absorption disorders are prohibited.
(4) Patients with diseases that may be aggravated by flatulence (such as Roche's syndrome, severe hernia, intestinal obstruction, postoperative intestinal surgery, intestinal ulcer, etc.) are prohibited.
(5) Patients with severe liver and renal insufficiency are prohibited.
Matters needing attention
(1) The patient should adjust the dose according to the doctor's advice.
(2) If the patient is taking medicine? The curative effect is not obvious after 8 weeks, so the dose can be increased. If the patient still feels uncomfortable in adhering to a strict diabetes diet, the dose cannot be increased, and sometimes it is necessary to reduce the dose appropriately. The average dose was 0. 1g each time, three times a day.
(3) Asymptomatic elevation of liver enzymes will occur in some patients, especially when large doses are used, which should be considered in the first 6? The changes of liver enzymes were monitored for 65438 02 months. After stopping the drug, the liver enzyme value will return to normal.
(4) If hypoglycemia occurs, it should be corrected with glucose instead of sucrose.
Medication for pregnant and lactating women
The safety of pregnant women is not clear, and the drug secretion in breast milk is tested on animals, which is not suitable for pregnant women and lactating women.
Children's medication
/kloc-Not suitable for use before 0/8 years old.
Medication for elderly patients
Lack of security foundation.
drug interaction
excessive
1. If this product is used with sulfonylureas, metformin or insulin, blood sugar may drop to hypoglycemia level, so the dosage of sulfonylureas, metformin or insulin should be reduced.
2. During taking this product, avoid taking antacid, cholestyramine, intestinal adsorbent and digestive enzyme preparation at the same time, so as not to affect the curative effect of this product.
3. Taking neomycin at the same time can reduce postprandial blood sugar and aggravate the gastrointestinal reaction of this product.
standard
50 mg
store
Keep away from light, seal and store in a cool place.
When the temperature is higher than 25℃ and the relative humidity is higher than 75%, the unpacked tablets will change color. Therefore, the tablets should be taken out of the package immediately before taking them.
parcel
Plastic plastic blister packaging, 15 pieces/plate, 1 plate or 2 plates/box.
term of validity
Registration authentication number
Production enterprise
Enterprise name:
Address:
Postal code:
Telephone number:
Fax number:
Website: